Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

The outcome of older (≥ 60 years) acute myeloid leukemia (AML) patients is poor, and novel treatments are needed. In a phase 2 trial for older AML patients, low-dose (20 mg/m(2) per day for 10 days) decitabine, a DNA hypomethylating azanucleoside, produced 47% complete response rate with an excellen...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Yan, Pearlly, Frankhouser, David, Murphy, Mark, Tam, Hok-Hei, Rodriguez, Benjamin, Curfman, John, Trimarchi, Michael, Geyer, Susan, Wu, Yue-Zhong, Whitman, Susan P., Metzeler, Klaus, Walker, Alison, Klisovic, Rebecca, Jacob, Samson, Grever, Michael R., Byrd, John C., Bloomfield, Clara D., Garzon, Ramiro, Blum, William, Caligiuri, Michael A., Bundschuh, Ralf, Marcucci, Guido
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2012
נושאים:
Myeloid Neoplasia
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3448258/
https://ncbi.nlm.nih.gov/pubmed/22786882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-429175
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים